Your browser doesn't support javascript.
loading
Clinical significance of dasatinib-induced pleural effusion in patients with de novo chronic myeloid leukemia.
Nakaya, Aya; Fujita, Shinya; Satake, Atsushi; Nakanishi, Takahisa; Azuma, Yoshiko; Tsubokura, Yukie; Hotta, Masaaki; Yoshimura, Hideaki; Ishii, Kazuyoshi; Ito, Tomoki; Nomura, Shosaku.
Afiliación
  • Nakaya A; First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
  • Fujita S; First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
  • Satake A; First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
  • Nakanishi T; First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
  • Azuma Y; First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
  • Tsubokura Y; First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
  • Hotta M; First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
  • Yoshimura H; First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
  • Ishii K; First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
  • Ito T; First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
  • Nomura S; First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Hematol Rep ; 10(3): 7474, 2018 Sep 05.
Article en En | MEDLINE | ID: mdl-30283618
Dasatinib is currently approved for clinical use as a first-line treatment agent for newly diagnosed chronic myeloid leukemia (CML). However, only a few clinical trials have been performed to evaluate dasatinibinduced PE following first-line therapy. We investigated the incidence and clinical features of dasatinib-induced PE following first-line therapy in Japanese CML patients of real world clinical practice settings. Among 22 patients, the median age of PE-positive patients was higher than that of PE-negative patients. Major molecular response was achieved in 75% of PE-positive patients and 50% of PE-negative patients. Most patients developed PE more than 1 year after treatment. Appearance of PE is associated with better clinical response during dasatinib treatment, however it is developed at any time. Elderly and high-risk patients tend to develop PE. The clinical features of dasatinib-induced PE following first-line therapy might be late onset and might not immediately follow the increasing of large granular lymphocyte.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Hematol Rep Año: 2018 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Hematol Rep Año: 2018 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Suiza